Pearl S Rosenbaum Selected Research

LXR 1035

11/2006

EDG receptors as a potential therapeutic target in retinal ischemia-reperfusion injury.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Pearl S Rosenbaum Research Topics

Disease

6	Ischemia 09/2011 - 08/2002
4	Reperfusion Injury 05/2010 - 08/2002
3	Necrosis 09/2011 - 09/2002
1	Uveitis 01/2011
1	Retinal Artery Occlusion 07/2010
1	Retinal Diseases 08/2002

Drug/Important Bio-Agent (IBA)

6	Retinaldehyde (Retinal)IBA 09/2011 - 08/2002
1	Peptides (Polypeptides)IBA 09/2011
1	calpain inhibitorsIBA 09/2011
1	CalpainIBA 09/2011
1	ProdrugsIBA 09/2011
1	Peptide Hydrolases (Proteases)FDA Link 09/2011
1	argininalIBA 09/2011
1	AntistreptolysinIBA 01/2011
1	Fluorescein (Funduscein)FDA LinkGeneric 07/2010
1	CaspasesIBA 05/2010
1	Death Domain ReceptorsIBA 05/2010
1	Neutralizing AntibodiesIBA 08/2008
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 08/2008
1	Sphingosine-1-Phosphate ReceptorsIBA 11/2006
1	Lysophosphatidic Acid ReceptorsIBA 11/2006
1	LXR 1035IBA 11/2006
1	Proteins (Proteins, Gene)FDA Link 09/2002
1	Phosphotransferases (Kinase)IBA 09/2002
1	salicylhydroxamic acid (SHAM)IBA 09/2002
1	Mitogen-Activated Protein KinasesIBA 09/2002
1	Caspase 2IBA 09/2002
1	Erythropoietin FDA Link 08/2002

Therapy/Procedure

1	Intravitreal Injections 11/2006